logo
  

Oxford Biomedica Appoints Frank Mathias As CEO

Oxford Biomedica Plc (OXB.L), a British gene and cell therapy company, said on Tuesday that it has appointed Frank Mathias as Chief Executive Officer, with effect from March 2023.

Mathias has served as CEO of Rentschler Biopharma SE since 2016. Prior to Rentschler, he was CEO of Medigene AG.

He had also worked in senior roles at major pharma companies including Amgen, Servier and Hoechst AG.

Roch Doliveux will remain as interim CEO of the firm until March 2023, when Mathias will fully take over the responsibility of CEO and Doliveux will resume the role of Non-Executive Chair.

On January 17, John Dawson, then CEO of Oxford Biomedica, had informed the Board his intention to retire from the company.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Google, owned by Alphabet Inc., plans to merge its teams working on Maps products and the mapping service Waze with effect from December 9, reports said. The decision to consolidate processes comes as the search giant is facing pressure to streamline operations and cut costs. The restructuring is expected to reduce overlapping work across the Waze and Maps products. The Pentagon announced that up to $9 billion worth of cloud-computing contracts were awarded to Google, Oracle, Amazon, and Microsoft. In a statement, the U.S. Department of Defense said, "The purpose of this contract is to provide the Department of Defense with enterprise-wide, globally available cloud services across all security domains and classification levels..." Juul Labs, an e-cigarette maker, said it has reached settlements with more than 5,000 vaping lawsuits in the United States. The cases were related to personal injury, consumer class action, government entity, and Native American tribes. In a statement, the company said it cannot disclose the settlement amount at this time as part of the settlement and court process.
RELATED NEWS
Follow RTT